Navigation Links
Increasing Affluence and Legislative Reforms are Transforming Poland's Pharmaceutical Market, Which Holds Strategic Importance for Multinational Companies
Date:10/23/2013

BURLINGTON, Mass., Oct. 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Poland's increasing affluence, as well as its myriad reforms and policy initiatives on healthcare quality, access, privatization and financing, have contributed to growth in the country's pharmaceutical market during much of the last decade. Poland has experienced several years of significant growth in public drug reimbursement expenditure. With a $4.7 billion prescription drug market in 2012, this large and populous central European country holds strategic importance for multinational companies looking beyond the major pharmaceutical markets for growth opportunities.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

However, according to the Poland Market Access Tracker, the market entry of multinationals in Poland is hampered by a number of challenges including the country's traditionally low prices for reimbursed drugs, its relatively high patient copayment levels, a large market share for generic drugs and its relatively low spend on healthcare as a percentage of gross domestic product. Additionally, the 2012 Reimbursement of Medicines, Foodstuffs Intended for Particular Nutritional Purposes and Medical Devices Act (commonly known as the "Reimbursement Act") has caused radical changes in drug assessment, pricing and reimbursement, and has—in a very short time frame—become one of the most restrictive reimbursement regulations in all Europe. After several years of healthy growth in the prescription drugs sector in Poland, the Reimbursement Act drove a sharp 13.4 percent decline in prescription drug sales in 2012.

"Poland's initiatives on improving the transparency of drug pricing and reimbursement and on the use of health technology assessment to foster cost-effective use of drugs can ultimately benefit innovators who show the clinical and economic benefits of their therapies to the Polish health system," said Decision Resources Analyst Laurie DiModica, M.S. "Drug manufacturers operating in Poland now have the opportunity to enter into risk-sharing agreements with the government based on clinical outcomes and expected cost savings. This has enabled drug makers to avoid the potential for a hefty payback required of manufacturers when the government's drug reimbursement spending exceeds 17 percent of the annual public healthcare budget. Further, the next few years will be critical to the industry, as the Polish government has signaled its intention to reallocate savings generated through the Reimbursement Act into increasing access to innovative, cost-effective medicines."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Increasing Incidence of Cardiovascular Diseases to Drive The Cardiovascular Devices Market in Emerging Countries
2. Pharma Execs Continue Looking For Growth Opportunities In Spite Of Increasing Regulatory Challenges: KPMG Survey
3. Diabetes Care Devices in Emerging Countries (China, India, Brazil) to 2017 - Greater Awareness is Increasing Demand for Self-Monitoring of Blood Glucose (SMBG) in the Home Care Segment
4. Cardiac Rhythm Management Devices Market to 2017 - Technological Innovations, Regulatory Approvals and Increasing Disease Prevalence Present Growth Opportunities
5. Patient Monitoring Devices Market to 2017 - Increasing Use of Wireless Remote Patient Monitoring to be the Key Technology Trend
6. Increasing Minimal Invasive Surgeries to Boost Adoption of Hybrid Operating Rooms in Europe, Says Frost & Sullivan
7. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
8. Patient Monitoring Devices Market in Emerging Countries (China, India, Brazil) to 2017 - Increasing Government Spending and Foreign Direct Investment (FDI) to Drive Future Growth
9. RMANJ Research Demonstrates That Egg Freezing Prior To IVF Yields Positive Outcomes Without Increasing Risk Of Aneuploidy
10. Global Hospital Supplies Market to 2018 - Increasing Preference for Electro-mechanical Tables over Conventional Hydraulic Models to Drive Market Growth: MarketResearchReports.Biz
11. AssureRx Health Expands Management Team to Support Increasing Business Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016   TriNetX , the health research ... signed a membership agreement to join the ... new cures. The TriNetX network is ... patients globally, biopharmaceutical companies and contract research organizations ... design, site selection, patient recruitment, and collaborative research ...
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals International, ... VRX) ("Valeant") today announced positive results from a ... to assess the safety and efficacy of IDP-118 ... of plaque psoriasis. Within the ... moderate to severe psoriasis, IDP-118 showed statistical significance ...
(Date:12/8/2016)... 8, 2016  EIP Pharma, LLC ( www.eippharma.com ... for neflamapimod (previously code named VX-745), with the ... trials that demonstrated significant Alzheimer,s disease relevant pharmacological ... and Study 303 (6-week treatment) are the subject ... Disease (CTAD) scientific conference in San ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental ... Your Mouth?” (WIYM) campaign to inform dentists and patients about the safety issues related ... and prosthetic market in the U.S. is projected to reach $6.4 billion in 2018 ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today announced ... was set up in 2006 as a non-profit organization to unite pharmaceutical and ...
(Date:12/8/2016)... ... 08, 2016 , ... Healthcare is in flux. The GOP ... the mass media launching of story movements to highlight what's most unfair about ... experiences; such a movement can generate the network power to improve healthcare policies ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter Zipp Insurance, an ... around the greater Phoenix metropolitan region, is announcing a charity event to provide ... the Homeless Youth Connection is to promote community awareness of the ongoing needs ...
(Date:12/7/2016)... ... 07, 2016 , ... DrugDev again demonstrated its dedication to reducing ... the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. ... sides of the Atlantic with a mechanism to comply with EU data protection requirements ...
Breaking Medicine News(10 mins):